#1 PRESCRIBED MONOCLONAL ANTIBODY TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA* *ACCORDING TO IQVIA CLAIMS DATA

DARZALEX *Faspro*®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

*For patients who are eligible for a stem cell transplant that uses their own stem cells**

VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).
*Eligibility is determined by your doctor.

WHEN MULTIPLE MYELOMA IS ANYTHING BUT QUIET

NEITHER AM I

If you've just been diagnosed with multiple myeloma and are eligible to receive a stem cell transplant that uses your own stem cells,*

Talk to your doctor about starting treatment with DARZALEX *FASPRO*® + VRd

What is DARZALEX *FASPRO*® (daratumumab and hyaluronidase-fihj)?

DARZALEX *FASPRO*® is a prescription medicine used to treat adult patients with multiple myeloma:

- in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)

SELECT IMPORTANT SAFETY INFORMATION

Do not receive DARZALEX *FASPRO*® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX *FASPRO*®. See below for a complete list of ingredients in DARZALEX *FASPRO*®.

Before you receive DARZALEX *FASPRO*®, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of breathing problems
- have had shingles (herpes zoster)
- have ever had or might now have a hepatitis B infection as DARZALEX *FASPRO*® could cause hepatitis B virus to become active again. Your healthcare provider will check you for signs of this infection before, during, and for some time after treatment with DARZALEX *FASPRO*®. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.
- are pregnant or plan to become pregnant. DARZALEX *FASPRO*® may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with DARZALEX *FASPRO*®.
  - Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARZALEX *FASPRO*®.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

Understanding multiple myeloma and treatment

1

Normal Bone Marrow

Bone marrow can be thought of as a garden. Healthy bone marrow is similar to thriving flowers without the threat of weeds.

2

Disease Diagnosis

A multiple myeloma diagnosis occurs when cancer cells begin to overtake your bone marrow. Early treatment is important. If left untreated, multiple myeloma can get worse over time.

3

Treatment Goals

Treatment aims to slow the growth of cancer cells to gain control of the disease. The goal of treatment is to control the growth of multiple myeloma cells.

4

Progression-Free Survival

Living progression-free can be thought of as the length of time that the disease does not get worse. This is a sign that the disease is under control—similar to controlling weeds in a garden.

For the best outcomes, it's important to start multiple myeloma treatment as soon as possible

Levels of response for multiple myeloma

There are many goals of multiple myeloma treatment. One goal is to live progression free. This can be thought of as the length of time that the disease does not get worse.

Treatment response is another key goal. This refers to how well the multiple myeloma cells in your body are being controlled by therapy. As response deepens (or gets better), fewer cancer cells remain.

You can think of response like weeds being treated in a garden. The weeds begin to disappear as treatment becomes more effective.

A multiple myeloma diagnosis can feel overwhelming, but you and your care team are in this together. If you have questions about your treatment goals, be sure to ask your team.

Achieving the deepest response for as long as possible is one goal of treatment

SOME RESPONSE

Partial Response
Treatment has started to help, but cancer cells still remain

DEEP RESPONSE

Very Good Partial Response
The treatment has started to go deeper—there are fewer cancer cells than before

DEEPER RESPONSE

Complete Response
There are no signs of cancer seen in imaging, blood, or bone marrow tests, but a small number of cells may still exist under the surface

Minimal Residual Disease (MRD) Negativity
The most sensitive tests available can detect a very small number of cancer cells. MRD negativity is currently the most sensitive way to determine how well a treatment works.



It's important to start with an effective multiple myeloma treatment first

A treatment plan that includes one or more medications is called a line of therapy. It may also include a stem cell transplant.

A change in treatment is considered a new line of therapy. This may happen if one or more treatments stop working or cause side effects. **You and your care team will work together to determine the right treatment for you.**

Research has shown that your best chance at deeper response occurs with your first line of therapy*



*In a retrospective study of 4,997 patient charts from 7 European countries.

Data rates may apply.

Resources are available to help you stay on track with treatment.

TREATING WITH DARZALEX *FASPRO*®

About DARZALEX *FASPRO*®

DARZALEX *FASPRO*® is used to treat adult patients with multiple myeloma. It is not chemotherapy. It's a type of immunotherapy called a monoclonal antibody. This means it works with your immune system to treat the cancer.

DARZALEX *FASPRO*® is made up of 2 main parts:

Daratumumab (pronounced da-ra-tu-mu-mab) is the ingredient that treats multiple myeloma. It directly kills multiple myeloma cells and/or helps your immune system find and destroy them.

Because of the way daratumumab works, it may also affect normal cells.

Hyaluronidase (pronounced hy-a-lur-on-i-dase) helps daratumumab to be injected into the skin and absorbed into the body.

Learn more about how DARZALEX *FASPRO*® works to treat multiple myeloma. Scan the QR code* or visit darzalex.com

*Data rates may apply.

SELECT IMPORTANT SAFETY INFORMATION (cont)

Do not receive DARZALEX *FASPRO*® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX *FASPRO*®. See below for a complete list of ingredients in DARZALEX *FASPRO*®.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

TREATING WITH DARZALEX *FASPRO*®

About DARZALEX *FASPRO*® + VRd

DARZALEX *FASPRO*® is used with other medicines, by itself, or together with a stem cell transplant, depending on your doctor's treatment plan. **One combination is DARZALEX *FASPRO*® + VRd** (bortezomib, lenalidomide, and dexamethasone), which is known as a quadruplet, or quad, therapy and consists of 4 treatments.

In this treatment combination, DARZALEX *FASPRO*® is:

For newly diagnosed patients who are deemed eligible to receive a type of stem cell transplant using their own stem cells*

Given in about 3 to 5 minutes under the skin in the stomach area by your healthcare provider†

Watch a video to learn more about the patient experience with DARZALEX *FASPRO*®
Scan the QR code* or visit **darzalex.com**

*Data rates may apply.

SELECT IMPORTANT SAFETY INFORMATION (cont)

DARZALEX *FASPRO*® may cause serious reactions, including:

Serious allergic reactions and other severe injection-related reactions. Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX *FASPRO*®. Your healthcare provider may temporarily stop or completely stop treatment with DARZALEX *FASPRO*® if you have a serious reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX *FASPRO*®.

For patients eligible for transplant, first-line therapy may include different treatment phases

Induction therapy

The first treatment given before stem cell transplant, aimed at reducing the number of cancer cells. It typically includes a combination of medicines

Stem cell transplant

A procedure that uses your own stem cells, which are collected, preserved, and infused into your bloodstream to restore blood cell production

Consolidation therapy

The same medications used for induction therapy, given over a shorter period of time to kill cancer cells that may be left in the body

Post-consolidation therapy

Following consolidation, your doctor may prescribe additional medication to maintain your results

VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*Your doctor will determine transplant eligibility.
†This refers to the injection administration time and does not account for all aspects of treatment.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

CLINICAL TRIAL DETAILS

DARZALEX *FASPRO*® was a critical part of first-line therapy before and after stem cell transplant

In a clinical trial, DARZALEX *FASPRO*® was studied in combination with bortezomib, lenalidomide, and dexamethasone (DARZALEX *FASPRO*® + VRd) in induction and consolidation, compared to treatment with VRd.

Who participated?

- 709 people
- Newly diagnosed with multiple myeloma
- Eligible to receive a type of stem cell transplant that uses the patient's own stem cells*

What were the goals of the study?

- The main goal was to measure how long patients lived without their multiple myeloma getting worse
- A second goal was to measure response to treatment using markers in blood, urine, and bone marrow

What treatments were compared?

DARZALEX *FASPRO*® + VRd Group		VRd Group
Induction therapy DARZALEX *FASPRO*® + VRd	Weeks 1 to 16	**Induction therapy** VRd
Stem cell transplant		**Stem cell transplant**
Consolidation therapy DARZALEX *FASPRO*® + VRd	Weeks 1 to 8†	**Consolidation therapy** VRd
Investigational post-consolidation therapy DARZALEX *FASPRO*® + R (DR) *This phase was investigational and not set up to determine the effect of DR. Therefore, treatment effectiveness post consolidation has not been proven.*		**Post-consolidation therapy** R

R=lenalidomide; VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*A doctor determined transplant eligibility for each patient.
†Treatment restarted at week 1 after recovery from stem cell transplant.

SELECT IMPORTANT SAFETY INFORMATION (cont)
The most common severe abnormal blood test results with DARZALEX *FASPRO*® included decreased white blood cells, platelets, and red blood cells.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

CLINICAL TRIAL RESULTS

In the DARZALEX *FASPRO*® + VRd group, more people lived progression-free

Disease progression* was 60% less likely with DARZALEX *FASPRO*® + VRd compared with VRd alone

85% **in the DARZALEX *FASPRO*® + VRd group lived without their disease getting worse after 48 months†**

compared with 67% in the VRd treatment group†

MRD=minimal residual disease; R=lenalidomide; VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*Disease progression refers to the length of time a patient lived without having their disease getting worse, or passing away.
†48-month estimate based on a median follow-up of 47.5 months for the DARZALEX *FASPRO*® + VRd and VRd groups.

In people who received DARZALEX *FASPRO*® + VRd for induction and consolidation:

45% (158 out of 355) **achieved complete response or better**

vs 35% (123 out of 354) in the VRd group

58% (204 out of 355) **achieved MRD negativity**

vs 33% (115 out of 354) in the VRd group

In people who achieved complete response or better during induction and consolidation, 77% (121 out of 158) on DARZALEX *FASPRO*® + VRd also achieved MRD negativity, compared with 59% (72 out of 123) treated with VRd alone

SELECT IMPORTANT SAFETY INFORMATION (cont)

The most common side effects of DARZALEX *FASPRO*® when used in combination therapy include:

- tiredness
- nausea
- diarrhea
- shortness of breath
- trouble sleeping
- headache
- rash
- fever
- cough
- muscle spasms
- back pain
- vomiting
- high blood pressure
- muscle, bone, and joint pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness, or pain
- constipation
- lung infection (pneumonia)
- swollen hands, ankles, or feet
- decreased red blood cell counts

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

Side effects for DARZALEX *FASPRO*®

Do not receive DARZALEX *FASPRO*® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX *FASPRO*®.
See page 13 for a complete list of ingredients in DARZALEX *FASPRO*®.

You may experience side effects from treatment. Side effects are an unwanted or unexpected reaction to a drug that can occur anywhere in your body.

Serious allergic reactions and other severe injection-related reactions

Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX *FASPRO*®. Your doctor or care team may temporarily stop or completely stop treatment if you have a serious reaction.

Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX *FASPRO*®:

- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
- cough
- wheezing
- heart beating faster than usual
- low oxygen in the blood (hypoxia)
- throat tightness or irritation
- runny or stuffy nose
- headache
- itching
- high blood pressure
- eye pain
- nausea
- vomiting
- chills
- fever
- chest pain
- blurred vision

In studies, injection-related reactions decreased over time

- 7% had a reaction with the first injection
- 0.5% had a reaction with the second injection
- 1% had a reaction with the following injections combined

Not everyone responds to treatment the same. Talk to your care team about any side effects that are bothersome or do not go away.

The most common side effects of DARZALEX *FASPRO*® when used alone are:

- cold-like symptoms (upper respiratory infection)
- decreased red blood cell counts

Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX *FASPRO*®.

In clinical studies, 8% of patients had an injection site reaction with DARZALEX *FASPRO*®.

Symptoms at the site of injection may include itching, swelling, bruising, pain, rash, bleeding, or redness of the skin.

Decreased blood cell counts and changes in blood tests

Your doctor will do blood tests to check your blood cell count and match your blood type before treatment. DARZALEX *FASPRO*® can:

- Decrease white blood cell counts (help fight infections) and blood cells called platelets (help clot blood). Decreases are common with DARZALEX *FASPRO*® but can be severe. Tell your doctor if you get a fever or develop signs of bruising or bleeding
- Affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX *FASPRO*®. **Tell all of your healthcare providers that you are being treated with DARZALEX *FASPRO*® before receiving blood transfusions**

The most common side effects of DARZALEX *FASPRO*® when used in combination with other therapies include:

- tiredness
- nausea
- diarrhea
- shortness of breath
- trouble sleeping
- headache
- rash
- fever
- cough
- muscle spasms
- back pain
- vomiting
- high blood pressure
- muscle, bone, and joint pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness, or pain
- constipation
- lung infection (pneumonia)
- swollen hands, ankles, or feet
- decreased red blood cell counts

These are not all of the possible side effects of DARZALEX *FASPRO*®. Speak with your doctor about the side effects that you may experience with DARZALEX *FASPRO*®.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

Dosing for DARZALEX *FASPRO*® when given in combination with VRd

INDUCTION: DARZALEX *FASPRO*® + VRd
(Given before stem cell transplant)

DARZALEX *FASPRO*® is given every week
Weeks 1 to 8 • *8 doses total*

DARZALEX *FASPRO*® is given every 2 weeks
Weeks 9 to 16 • *4 doses total*

Stop for high-dose chemotherapy and a stem cell transplant that uses your own stem cells

CONSOLIDATION: DARZALEX *FASPRO*® + VRd
(Given after stem cell transplant)

DARZALEX *FASPRO*® is given every 2 weeks
Weeks 1 to 8* • *4 doses total*

Your care team will determine the dosing for bortezomib (V), lenalidomide (R), and dexamethasone (d) using each drug's product information

R=lenalidomide; VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*Treatment restarted at week 1 after recovery from stem cell transplant.

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

*Data rates may apply.

Learn more about how DARZALEX *FASPRO*® works to treat multiple myeloma. Scan the QR code* or visit darzalex.com

Prescribed DARZALEX *FASPRO*®?

Get personalized 1-on-1 support from a Care Navigator.
Call 1-844-628-1234 or visit darzalex.com to learn more

SELECT IMPORTANT SAFETY INFORMATION (cont)

Do not receive DARZALEX *FASPRO*® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX *FASPRO*®. See below for a complete list of ingredients in DARZALEX *FASPRO*®.

What to expect with treatment

1 Preparation

Dress for comfort.
Wear clothing that is loose around the waist. DARZALEX *FASPRO*® is injected about 3 inches to the left or right of the belly button.

Set aside enough time.
Additional time may be needed for pre-medication, lab work, and monitoring for side effects.

2 Before your injection

You may be given medicines before and after each dose of DARZALEX *FASPRO*® to help prevent allergic reactions, inflammation, and/or fever. A quick physical exam or blood test may be performed.

Before you receive DARZALEX *FASPRO*®, tell your care team about all of your medical conditions, including if you:

- have a history of breathing problems
- have had shingles
- have ever had or might now have a hepatitis B infection
- are pregnant or planning to become pregnant
- are breastfeeding or plan to breastfeed

*Data rates may apply.

Learn more about what to expect from treatment. Scan the QR code* or visit darzalex.com

3 During your injection



Your healthcare provider will prepare the syringe



An injection site on your stomach will be chosen and prepared



The injection will be completed in about 3 to 5 minutes*

*This refers to the injection administration time and does not account for all aspects of treatment.

4 After treatment

Pay attention to how you feel and tell your care team about any discomfort during or after treatment, and especially during the first and second injections. It could mean you may be having a reaction to the treatment. **Your healthcare provider may want you to remain in the office to watch for any side effects.**

Injection site reactions: Skin reactions at or near the injection site (local), including injection site reactions listed on page 13, can happen with DARZALEX *FASPRO*®. These reactions sometimes happen more than 24 hours after an injection of DARZALEX *FASPRO*®.

Post medication: After your injection, you may also be given oral corticosteroids to reduce the risk of delayed reactions to DARZALEX *FASPRO*®.

SELECT IMPORTANT SAFETY INFORMATION (cont)

Changes in blood tests. DARZALEX *FASPRO*® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX *FASPRO*®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX *FASPRO*®. **Tell all of your healthcare providers that you are being treated with DARZALEX *FASPRO*® before receiving blood transfusions.**

Please see Important Safety Information on pages 12-13.
Please see Important Product Information here.

Indications and Important Safety Information for DARZALEX *FASPRO*®

What is DARZALEX *FASPRO*® (daratumumab and hyaluronidase-fihj)?

DARZALEX *FASPRO*® is a prescription medicine used to treat adult patients with multiple myeloma:

- in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines bortezomib, melphalan, and prednisone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant) and in people whose multiple myeloma has come back or did not respond to treatment who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines bortezomib, thalidomide, and dexamethasone in newly diagnosed people who are eligible to receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant)
- in combination with the medicines bortezomib and dexamethasone in people who have received at least one prior medicine to treat multiple myeloma
- in combination with the medicines pomalidomide and dexamethasone in people who have received at least one prior medicine, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma
- in combination with the medicines carfilzomib and dexamethasone in people whose multiple myeloma has come back or did not respond to treatment who have received one to three prior medicines to treat multiple myeloma
- alone in people who have received at least three prior medicines, including a proteasome inhibitor and an immunomodulatory agent, **or** did not respond to a proteasome inhibitor and an immunomodulatory agent

It is not known if DARZALEX *FASPRO*® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not receive DARZALEX *FASPRO*® if you have a history of a severe allergic reaction to daratumumab, hyaluronidase, or any of the ingredients in DARZALEX *FASPRO*®. See below for a complete list of ingredients in DARZALEX *FASPRO*®.

Before you receive DARZALEX *FASPRO*®, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of breathing problems
- have had shingles (herpes zoster)
- have ever had or might now have a hepatitis B infection as DARZALEX *FASPRO*® could cause hepatitis B virus to become active again. Your healthcare provider will check you for signs of this infection before, during, and for some time after treatment with DARZALEX *FASPRO*®. Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.
- are pregnant or plan to become pregnant. DARZALEX *FASPRO*® may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with DARZALEX *FASPRO*®.
  - Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of DARZALEX *FASPRO*®. Talk to your healthcare provider about birth control methods that you can use during this time.
  - Before starting DARZALEX *FASPRO*® in combination with lenalidomide, thalidomide, or pomalidomide, females and males must agree to the instructions in the lenalidomide, thalidomide, or pomalidomide REMS program.
    - The lenalidomide, thalidomide, and pomalidomide REMS have more information about effective methods of birth control, pregnancy testing, and blood donation for females who can become pregnant.
    - For males who have female partners who can become pregnant, there is information in the lenalidomide, thalidomide, and pomalidomide REMS about sperm donation and how lenalidomide, thalidomide, and pomalidomide can pass into human semen.
- are breastfeeding or plan to breastfeed. It is not known if DARZALEX *FASPRO*® passes into your breast milk. You should not breastfeed during treatment with DARZALEX *FASPRO*®. Talk to your healthcare provider about the best way to feed your baby during treatment with DARZALEX *FASPRO*®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX *FASPRO*®?

- DARZALEX *FASPRO*® may be given alone to treat multiple myeloma or together with other medicines used to treat multiple myeloma
- DARZALEX *FASPRO*® will be given to you by your healthcare provider as an injection under the skin in the stomach area (abdomen).
- DARZALEX *FASPRO*® is injected over 3 to 5 minutes.

Continued on next page

Indications and Important Safety Information for DARZALEX *FASPRO*® (cont)

- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of DARZALEX *FASPRO*® and after each dose of DARZALEX *FASPRO*® to help reduce the risk of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

DARZALEX *FASPRO*® may cause serious reactions, including:

- **Serious allergic reactions and other severe injection-related reactions.** Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death can happen with DARZALEX *FASPRO*®. Your healthcare provider may temporarily stop or completely stop treatment with DARZALEX *FASPRO*® if you have a serious reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an injection of DARZALEX *FASPRO*®.
  - shortness of breath or trouble breathing
  - dizziness or lightheadedness (hypotension)
  - cough
  - wheezing
  - heart beating faster than usual
  - low oxygen in the blood (hypoxia)
  - throat tightness or irritation
  - runny or stuffy nose
  - headache
  - itching
  - high blood pressure
  - eye pain
  - nausea
  - vomiting
  - chills
  - fever
  - chest pain
  - blurred vision
- **Injection site reactions.** Skin reactions at or near the injection site (local), including injection site reactions, can happen with DARZALEX *FASPRO*®. Symptoms at the site of injection may include itching, swelling, bruising, pain, rash, bleeding, or redness of the skin. These reactions sometimes happen more than 24 hours after an injection of DARZALEX *FASPRO*®.
- **Infections.** DARZALEX *FASPRO*® can cause serious life-threatening infections that can lead to death. Tell your healthcare provider right away if you develop a fever, trouble breathing, cough, burning or pain when you urinate, or any other signs and symptoms of infection during treatment.
- **Decreases in blood cell counts.** DARZALEX *FASPRO*® can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Decreases in blood cell counts are common with DARZALEX *FASPRO*® and can be severe. Your healthcare provider will check your blood cell counts during treatment with DARZALEX *FASPRO*®. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.
- **Changes in blood tests.** DARZALEX *FASPRO*® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX *FASPRO*®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX *FASPRO*®. **Tell all of your healthcare providers that you are being treated with DARZALEX *FASPRO*® before receiving blood transfusions.**

The most common side effects of DARZALEX *FASPRO*® when used alone include:

- cold-like symptoms (upper respiratory tract infection)
- muscle, bone, and joint pain
- tiredness
- diarrhea
- rash
- trouble sleeping, including sleep apnea and restless legs
- nerve problems, including increased or decreased sensitivity to touch, temperature, or pain; loss of smell; and numbness, tingling, or burning sensations
- injection site reactions

The most common side effects of DARZALEX *FASPRO*® when used in combination therapy include:

- tiredness
- nausea
- diarrhea
- shortness of breath
- trouble sleeping
- headache
- rash
- fever
- cough
- muscle spasms
- back pain
- vomiting
- high blood pressure
- muscle, bone, and joint pain
- cold-like symptoms (upper respiratory infection)
- nerve damage causing tingling, numbness, or pain
- constipation
- lung infection (pneumonia)
- swollen hands, ankles, or feet
- decreased red blood cell counts

The most common severe abnormal blood test results with DARZALEX *FASPRO*® include decreased white blood cells, platelets, and red blood cells.

These are not all of the possible side effects of DARZALEX *FASPRO*®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX *FASPRO*®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about DARZALEX *FASPRO*® that is written for health professionals.

Active ingredient: daratumumab and hyaluronidase-fihj

Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, water for injection

Please click here to read full Prescribing Information for DARZALEX *FASPRO*®.

cp-143282v12

Resources and support for your DARZALEX *FASPRO*® + VRd treatment journey



Watch Todd and Diane's story

Hear from Todd, a newly diagnosed, transplant-eligible patient, along with his wife and care partner, Diane, about their experience with DARZALEX *FASPRO*® + VRd

See all patient stories >

Data rates may apply.



Get personalized 1-on-1 support from a Care Navigator

You have access to free, dedicated support. Your Care Navigator is here to help throughout your treatment journey. Call 1-844-628-1234 or visit darzalex.com to learn more

Sign up for support >

Data rates may apply.

Access more helpful resources for DARZALEX *FASPRO*®

Download support materials, view treatment videos, and learn more about DARZALEX *FASPRO*® at darzalex.com

Explore resources >

Data rates may apply.

If you've been newly diagnosed with multiple myeloma and are eligible for a stem cell transplant,*

Ask your doctor if DARZALEX *FASPRO*® + VRd may be right for you

VRd=bortezomib (V) + lenalidomide (R) + dexamethasone (d).

*Your doctor will determine transplant eligibility.

Johnson&Johnson